自我监测血糖设备市场、机会、成长动力、产业趋势分析与预测，2024-2032

在第 1 型糖尿病盛行率不断上升的推动下，自我监测血糖设备市场规模在 2024 年至 2032 年期间将以 11.6% 的复合年增长率成长。据世界卫生组织称，全球约有 4.22 亿人患有糖尿病，其中大多数居住在低收入和中等收入国家。每年，糖尿病直接导致全球 150 万人死亡。 1 型糖尿病需要持续监测血糖水平，因此需要使用可靠的 SMBG 设备。对这种疾病及其早期诊断的更广泛认识正在推动 SMBG 技术的进步，从而导致更准确、用户友好和创新设备的开发。

现代 SMBG 设备可提供更高的血糖测量精度，减少错误并确保资料可靠，以实现有效的糖尿病管理。使用者友善的设计，包括简单的介面、最少的血液样本要求和快速的结果显示，使这些设备更容易被更广泛的使用者使用，包括老年人和技术能力有限的人。此外，自动资料记录、与行动应用程式整合和语音指导指令等进步进一步简化了监测过程，提高了患者的依从性和整体满意度。

自我监测血糖设备产业根据产品、应用、最终用途和地区进行分类。

到 2032 年，1 型糖尿病市场将快速成长，因为它需要持续监测血糖水平。血糖仪、试纸和刺血针等自我监测血糖 (SMBG) 设备已成为第 1 型糖尿病患者有效管理病情的重要工具。准确性的提高、易用性以及与数位健康平台的整合是这些设备在第 1 型糖尿病患者中广泛采用的关键因素。

到 2032 年，家庭护理领域将实现稳定增长。 SMBG 设备与智慧型手机和远距医疗平台的整合进一步促进了远端监控和咨询，提高了患者的依从性和整体疾病管理。

在糖尿病高盛行率、有利的医疗政策和技术进步的共同推动下，欧洲自我血糖监测设备产业将在 2024 年至 2032 年期间大幅成长。欧洲医疗保健系统对预防保健和慢性病管理的重视支持了自我监测设备的广泛使用。此外，旨在减轻糖尿病负担的政府措施和报销政策正在鼓励整个欧洲采用 SMBG 设备。

目录

第 1 章：方法与范围

第 2 章：执行摘要

第 3 章：产业洞察

• 产业生态系统分析
• 产业影响力
  • 成长动力
    • 全球糖尿病盛行率上升
    • 已开发国家的技术进步
    • 政府为提高人们的意识而采取的倡议
  • 产业陷阱与挑战
    • 发展中国家的先进设备和配件成本高昂
    • SMBG 设备缺乏报销和严格的法规
• 成长潜力分析
• 监管环境
• 技术景观
• 未来市场趋势
• 波特的分析
• PESTEL分析

第 4 章：竞争格局

• 介绍
• 公司市占率分析
• 公司矩阵分析
• 主要市场参与者的竞争分析
• 竞争定位矩阵
• 战略仪表板

第 5 章：市场估计与预测：按产品分类，2018 年 - 2032 年

• 主要趋势
• 自我监测血糖仪
• 耗材
  • 测试条
  • 柳叶刀

第 6 章：市场估计与预测：按应用划分，2018 年 - 2032 年

• 主要趋势
• 1 型糖尿病
• 2型糖尿病
• 妊娠糖尿病

第 7 章：市场估计与预测：按最终用途，2018 - 2032 年

• 主要趋势
• 医院
• 门诊手术中心
• 诊断中心
• 居家护理
• 其他最终用户

第 8 章：市场估计与预测：按地区划分，2018 年 - 2032 年

• 主要趋势
• 北美洲
  • 我们
  • 加拿大
• 欧洲
  • 德国
  • 英国
  • 法国
  • 西班牙
  • 义大利
  • 荷兰
  • 欧洲其他地区
• 亚太地区
  • 中国
  • 日本
  • 印度
  • 澳洲
  • 韩国
  • 亚太地区其他地区
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
  • 拉丁美洲其他地区
• 中东和非洲
  • 南非
  • 沙乌地阿拉伯
  • 阿联酋
  • 中东和非洲其他地区

第 9 章：公司简介

• Abbott Laboratories
• AgaMatrix
• All Medicus Co., Ltd.
• Arkray, Inc.
• Ascensia Diabetes Care Holdings AG
• B. Braun Melsungen AG
• Bionime Corporation
• DarioHealth Corp.
• Dexcom, Inc.
• Essenlife Bioscience, Inc.
• F. Hoffmann-La Roche Ltd.
• LifeScan Inc.
• Medtronic plc
• Nova Biomedical, Inc.
• Sinocare Inc.

The Self-monitoring Blood Glucose Devices Market size will grow at an 11.6% CAGR during 2024-2032, driven by the increasing prevalence of Type 1 diabetes. According to WHO, approximately 422 million people globally are living with diabetes, with the majority residing in low- and middle-income countries. Each year, diabetes directly accounts for 1.5 million deaths worldwide. Type 1 diabetes requires continuous monitoring of blood glucose levels, necessitating the use of reliable SMBG devices. The wider awareness about the condition and its early diagnosis is driving advancements in SMBG technology, leading to the development of more accurate, user-friendly, and innovative devices.

Modern SMBG devices offer higher precision in blood glucose measurements, reducing errors and ensuring reliable data for effective diabetes management. User-friendly designs, including simple interfaces, minimal blood sample requirements, and rapid result display, are making these devices more accessible to a broader range of users, including the elderly and those with limited technical skills. Additionally, advancements such as automated data logging, integration with mobile apps, and voice-guided instructions are further simplifying the monitoring process, enhancing patient compliance and overall satisfaction.

The self-monitoring blood glucose devices industry is classified based on product, application, end-use, and region.

The type 1 diabetes segment will grow rapidly through 2032, as it necessitates continuous monitoring of blood glucose levels. Self-monitoring blood glucose (SMBG) devices, such as glucometers, test strips, and lancets, have become essential tools for individuals with Type 1 diabetes to manage their condition effectively. Enhanced accuracy, ease of use, and integration with digital health platforms are among the key factors contributing to the widespread adoption of these devices among Type 1 diabetes patients.

The home care segment will witness steady growth through 2032. Home care offers a convenient and cost-effective alternative to hospital visits, allowing patients to monitor their blood glucose levels in the comfort of their homes. The integration of SMBG devices with smartphones and telehealth platforms further facilitates remote monitoring and consultation, enhancing patient compliance and overall disease management.

Europe self-Monitoring blood glucose devices industry will significantly over 2024-2032, driven by a combination of high diabetes prevalence, favorable healthcare policies, and technological advancements. The European healthcare system's emphasis on preventive care and chronic disease management supports the widespread use of self-monitoring devices. Additionally, government initiatives and reimbursement policies aimed at reducing the burden of diabetes are encouraging the adoption of SMBG devices across Europe.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising prevalence of diabetes worldwide
    • 3.2.1.2 Technological advancements in developed countries
    • 3.2.1.3 Government initiatives for increasing awareness among people
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 High cost of advanced devices and accessories in developing countries
    • 3.2.2.2 Lack of reimbursement and stringent regulations for SMBG devices
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Technological landscape
• 3.6 Future market trends
• 3.7 Porter's analysis
• 3.8 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Product, 2018 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Self-monitoring blood glucose meters
• 5.3 Consumables
  • 5.3.1 Testing strips
  • 5.3.2 Lancets

Chapter 6 Market Estimates and Forecast, By Application, 2018 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Type 1 diabetes
• 6.3 Type 2 diabetes
• 6.4 Gestational diabetes

Chapter 7 Market Estimates and Forecast, By End-use, 2018 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Hospitals
• 7.3 Ambulatory surgery centers
• 7.4 Diagnostic centers
• 7.5 Home care
• 7.6 Other end-users

Chapter 8 Market Estimates and Forecast, By Region, 2018 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 France
  • 8.3.4 Spain
  • 8.3.5 Italy
  • 8.3.6 Netherlands
  • 8.3.7 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 South Korea
  • 8.4.6 Rest of Asia Pacific
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Mexico
  • 8.5.3 Argentina
  • 8.5.4 Rest of Latin America
• 8.6 Middle East and Africa
  • 8.6.1 South Africa
  • 8.6.2 Saudi Arabia
  • 8.6.3 UAE
  • 8.6.4 Rest of Middle East and Africa

Chapter 9 Company Profiles

• 9.1 Abbott Laboratories
• 9.2 AgaMatrix
• 9.3 All Medicus Co., Ltd.
• 9.4 Arkray, Inc.
• 9.5 Ascensia Diabetes Care Holdings AG
• 9.6 B. Braun Melsungen AG
• 9.7 Bionime Corporation
• 9.8 DarioHealth Corp.
• 9.9 Dexcom, Inc.
• 9.10 Essenlife Bioscience, Inc.
• 9.11 F. Hoffmann-La Roche Ltd.
• 9.12 LifeScan Inc.
• 9.13 Medtronic plc
• 9.14 Nova Biomedical, Inc.
• 9.15 Sinocare Inc.